Ключевые слова:
острый лимфобластный лейкоз, минимальная остаточная болезнь, рецидив, бортезомиб.Библиографические ссылки
Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011; 29(5):532–543. doi:10.1200/JCO.2010.30.1382
Brüggemann M, Raff T, Kneba M. Has MRD monitoring superseded other prognostic factors in adult ALL? Blood. 2012; 120(23): 4470–4481. doi:10.1182/blood-2012-06-379040
Szczepański T. Why and how to quantify minimal residual disease in acute lymphoblastic leukemia? Leukemia. 2007;21(4):622–626. doi:10.1038 /sj.leu.2404603
Campana D. Minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2010; 2010:7–12. doi:10.11 82/asheducation-2010.1.7
Dworzak MN, Führing-Bohhem J, Printz D, et al. Detection and characterization of early T-cell precursor (ETP) acute lymphoblastic leukaemia by multiparameter flow cytometry. J Immunol Methods. 2012; 382(1-2): 39–48. doi:10.1016/j.jim.2012.05. 008
Wood B, Wu D, Crossley B, et al. Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood. 2018; 131(12):1350–1359. doi:10.1182 /blood-2017-09-806521